Rankia España
Acceder

Participaciones del usuario anaramos

08/10/19 08:42
Ha respondido al tema Farmas USA
EXELSupongo. La noticia ya se había hecho efectiva (lo colgué), pero la otra empresa había fallado en la obligación de notificarlo. Claro que, si se saltan la patente a la torera... Me preguntaba de repente anteayer si este tipo de intentos de genérico van siempre en serio o pueden ser también una manera de tirar cotizaciones...
Ir a respuesta
08/10/19 00:12
Ha respondido al tema Farmas USA
EXELAhora parece que sí es oficialreceived a Paragraph IV Certification Notice Letter from MSN Pharmaceuticals, Inc. (“MSN”) that MSN had filed an Abbreviated New Drug Application (“ANDA”) with the U.S. Food and Drug Administration (“FDA”) for a generic version of CABOMETYX® (cabozantinib) tablets (20 mg / 40 mg / 60 mg) (the “Notice”).The Notice states that MSN intends to market a generic version of CABOMETYX before the expiration of Exelixis’ U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, all of which are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book (the “Subject Patents”). The Notice does not challenge the CABOMETYX composition of matter patent No. 7,579,473, which expires on August 14, 2026. The Notice alleges that the Subject Patents are invalid, unenforceable and/or will not be infringed by MSN’s commercial manufacture, use or sale or the subject drug products.Exelixis currently is reviewing the Notice. The Company intends to vigorously enforce its intellectual property rights relating to CABOMETYX, but cannot predict the outcome of this matter. CABOMETYX is protected by six issued patents in the United States, all of which are listed in the Orange Book.
Ir a respuesta
05/10/19 15:31
Ha respondido al tema Farmas USA
Stocks staged an impressive rally Friday in reaction to the "Goldilocks" September jobs report, as the 136,000 new jobs created were seen as high enough to ease concerns that the U.S. is headed for a recession while also being low enough to keep hope alive that the Fed will keep cutting interest rates. The rally was broad-based, with all 11 S&P industry groups finishing higher, led by financials and information technology, although trading volume was a bit on the light side
Ir a respuesta
04/10/19 16:29
Ha respondido al tema Farmas USA
EXELFuera 17.22Edito: te he leído tarde, @Framus. Gracias. Supongo que debería haber esperado a esos 16 altos, pero veo mucha presión por tirarla (y también ganas de comprar).
Ir a respuesta
04/10/19 15:57
Ha respondido al tema Farmas USA
EXELParece que quiere cargarse el mínimo de 15.31 de hace unos día. Sigo a la espera.Edito: lo ha respetado en el primer intento. A ver la media hora que viene...Edito 2: entro media carga 17.44Edito 3: ha roto los 17.30
Ir a respuesta
04/10/19 11:14
Ha respondido al tema Farmas USA
EXELSale por ahí la noticia de "insider sells". Como pasa a menudo, vende porque se hace con otras tantas. Si me da oportunidad hoy sobre los 17 medios creo que no me resistiré, que ha aguantado bien la zona estos últimos 3 días.
Ir a respuesta
02/10/19 14:25
Ha respondido al tema Farmas USA
Markets are still on edge following data that showed U.S. factory activity shrinking in September to its weakest level since 2009, ratcheting up fears that the U.S.-China trade war is hobbling the world's largest economy. The weak print saw the Dow drop nearly 350 points yesterday - with another 173-point loss likely at the open - while stocks flashed red across Europe and Asia overnight. Wall Street's next focus is this morning's ADP private payrolls report, which will give further clues about the labor market and broader economy ahead of the government's monthly jobs report on Friday.
Ir a respuesta
01/10/19 18:30
Ha respondido al tema Farmas USA
TGTXDe ayerTG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in Bloodhttp://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-publication-clinical-data-phase-iib
Ir a respuesta
01/10/19 15:42
Ha respondido al tema Farmas USA
TEVASube por  by taking part in Purdue Pharma's bankruptcy. Johnson & Johnson (NYSE:JNJ), Teva (NYSE:TEVA), Endo International (NASDAQ:ENDP), Allergan (NYSE:AGN) and Mallinckrodt (NYSE:MNK) are pursuing a global settlement of litigation through Purdue's Chapter 11 case, according to the report. That would be through contributing to a trust in the case in exchange for release from liability. The mechanism is not dissimilar to one available to automakers in the Takata defective airbag litigation. It would need buy-in not only from Purdue and the owning Sackler family but also a critical mass of state AGs and suing municipalities -- and there are some 2,500 lawsuits brought by virtually every state along with local governments and Native American tribes. https://seekingalpha.com/news/3502762-drugmakers-pursue-new-plan-wrap-opioid-suits?ifp=0
Ir a respuesta

Este sitio web usa cookies para analizar la navegación del usuario. Política de cookies.
Cerrar